Login to Your Account



Prime Time for Five Prime in IPO Filing

By Marie Powers
Staff Writer

Tuesday, July 30, 2013
Protein and antibody drug developer Five Prime Therapeutics Inc. became the newest member of the class of 2013 biotech initial public offerings (IPOs) by filing an S-1 seeking to raise up to $60 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription